This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| IL-21 | |
|---|---|
| Name | Interleukin-21 |
| Other names | IL-21 |
| Family | Common gamma-chain family |
| Gene | IL21 |
| Organism | Homo sapiens |
IL-21 IL-21 is a type I cytokine involved in lymphoid cell regulation and adaptive immunity. It was characterized in studies involving Howard Hughes Medical Institute, National Institutes of Health, and research groups at The Scripps Research Institute, with implications for diseases studied at institutions like Mayo Clinic and Massachusetts General Hospital. IL-21 intersects pathways investigated in contexts such as HIV/AIDS, multiple sclerosis, rheumatoid arthritis, and melanoma immunotherapy.
IL-21 was discovered during cytokine cloning efforts paralleling work at Genentech, Amgen, and academic laboratories affiliated with University of California, San Francisco and University of Pennsylvania. Early reports appeared alongside descriptions of cytokines like Interleukin-2, Interleukin-4, and Interleukin-15 and within paradigms influenced by researchers at Harvard Medical School and Stanford University School of Medicine. Subsequent research connected IL-21 to mechanisms described in studies of CD4+ T cells, B lymphocytes, natural killer cells, and transcription factors characterized at Rockefeller University and Cold Spring Harbor Laboratory.
The IL21 gene is located on human chromosome 4 and encodes a 131‑amino‑acid precursor studied using techniques developed at European Molecular Biology Laboratory and Max Planck Institute. Structural characterization leveraged methods from Rosalind Franklin-era crystallography frameworks and modern approaches advanced at European Synchrotron Radiation Facility and Brookhaven National Laboratory. Comparative genomics analyses referencing data from Human Genome Project consortia and databases curated at UCSC Genome Browser and Ensembl revealed conserved motifs across vertebrates in line with members of the common gamma-chain family described in the literature from Cold Spring Harbor groups. Polymorphisms in IL21 were examined in cohorts recruited through networks including Framingham Heart Study and UK Biobank.
IL-21 expression is predominantly induced in activated CD4+ T cell subsets such as T follicular helper cells identified in studies at Dana-Farber Cancer Institute and Th17 cells explored at Johns Hopkins University School of Medicine. Induction mechanisms were mapped with chromatin techniques pioneered at Broad Institute and transcriptional profiling platforms developed at Illumina and Affymetrix. Key regulatory inputs include signaling modules linked to proteins studied at Max Planck Institute of Immunobiology and cytokines like Interleukin-6, Interleukin-12, and Transforming growth factor beta pathways analyzed in projects at EMBO and Cold Spring Harbor Laboratory. Epigenetic regulation has been evaluated using assays popularized by teams at Whitehead Institute and sequencing centers such as Wellcome Sanger Institute.
IL-21 exerts pleiotropic effects on lymphoid cells, influencing B cell differentiation in germinal centers studied in the context of Germinal center research at Institute Pasteur and plasma cell generation explored at Karolinska Institutet. It modulates cytotoxicity of NK cells investigated in collaborations with Fred Hutchinson Cancer Center and CD8+ T cell responses central to work at Memorial Sloan Kettering Cancer Center. Roles in antibody class switching and affinity maturation were delineated alongside studies of B cell receptor dynamics at Yale School of Medicine and vaccine responses evaluated in trials coordinated by Centers for Disease Control and Prevention. IL-21 impacts metabolic and apoptotic programs described in research streams associated with Salk Institute and Massachusetts Institute of Technology.
IL-21 signals via a heterodimeric receptor composed of a private alpha subunit and the common gamma chain, a paradigm first clarified in signaling literature from National Cancer Institute groups and laboratories at University of Cambridge. Downstream activation engages Janus kinases and STAT family transcription factors, particularly STAT3, with mechanistic insights stemming from studies at Institute of Cancer Research and Weizmann Institute of Science. Cross-talk with pathways involving PI3K-AKT and MAPK cascades echoes findings from signaling centers at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory. Mutations in receptor components are relevant to phenotypes described by clinicians at Great Ormond Street Hospital and geneticists associated with Wellcome Trust projects.
Aberrant IL-21 activity has been implicated in autoimmune conditions such as systemic lupus erythematosus, with cohorts reported from Mayo Clinic and University of Toronto, and in rheumatoid arthritis studied at Karolinska Universitetssjukhuset. Contributions to chronic viral infections including hepatitis and HIV were examined in consortia involving WHO and UNAIDS surveillance networks. Elevated IL-21 signaling has been associated with inflammatory bowel disease phenotypes investigated at Cleveland Clinic and allergy and asthma endotypes explored in research at Vanderbilt University Medical Center. Oncology studies implicate IL-21 in tumor immunity modulation in contexts such as melanoma and non-small cell lung carcinoma with clinical research across MD Anderson Cancer Center and University College London Hospitals NHS Trust.
IL-21 has been tested as a recombinant immunotherapeutic and targeted via monoclonal antibodies in trials conducted by pharmaceutical companies like Roche, Novartis, and GlaxoSmithKline and academic trials at National Institutes of Health Clinical Center. Combination strategies pairing IL-21 modulation with checkpoint inhibitors emerging from Memorial Sloan Kettering Cancer Center and adoptive cell therapies developed at Fred Hutchinson Cancer Center have entered early-phase studies. Biomarker-driven trials incorporate assays from Food and Drug Administration-regulated laboratories and translational platforms at Translational Research Institute. Ongoing research addresses safety, dosing, and efficacy endpoints in multicenter studies overseen by networks including European Medicines Agency and International Conference on Harmonisation guidelines.
Category:Cytokines